praziquantel
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Schistosomiasis
Conditions
Schistosomiasis
Trial Timeline
Aug 1, 2008 → Sep 1, 2012
NCT ID
NCT01558336About praziquantel
praziquantel is a phase 3 stage product being developed by Hikma Pharmaceuticals for Schistosomiasis. The current trial status is completed. This product is registered under clinical trial identifier NCT01558336. Target conditions include Schistosomiasis.
What happened to similar drugs?
0 of 1 similar drugs in Schistosomiasis were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
17
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01558336 | Phase 3 | Completed |
Competing Products
3 competing products in Schistosomiasis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Praziquantel 600Mg Oral Tablet x 5 + Praziquantel 600Mg Oral Tablet x 1 | Merck | Phase 2/3 | 38 |
| Biltricide (racemate praziquantel) oral tablets + Racemate Praziquantel ODT + Levo Praziquantel ODT | Merck | Phase 2 | 35 |
| L-PZQ ODT 50 mg/kg + Biltricide® + L-PZQ ODT 60 mg/kg | Merck | Phase 3 | 40 |